Anhedonia is associated with a specific depression profile and poor antidepressant response

Int J Neuropsychopharmacol. 2024 Dec 1;27(12):pyae055. doi: 10.1093/ijnp/pyae055.

Abstract

Background: Anhedonic features within major depressive disorder (MDD) have been associated with worse course and outcome and may predict nonresponse to treatment. However, a detailed clinical profile of anhedonia in MDD is still lacking.

Materials and methods: One thousand two hundred ninety-four patients with MDD were selected from the cross-sectional European multicenter Group for the Study of Resistant Depression study. Anhedonia was assessed through the Montgomery-Åsberg Depression Rating Scale anhedonia item "inability to feel." Clinical and demographic features were then analyzed.

Results: The presence of anhedonia related to a distinct demographical (living alone) and clinical profile (thyroid diseases, diabetes, suicide risk, high number of previous depressive episodes, more severe MDD, and more frequent inpatient status). Furthermore, anhedonia was associated with nonresponse to treatment and treatment resistance, even after adjusting for confounding variables.

Conclusions: Our findings support the role of anhedonia as a modulating feature of MDD, being associated with a more severe depression profile. Moreover, anhedonic features are independent predictors of poor treatment response.

Keywords: anhedonia; antidepressants; major depression; treatment outcomes; treatment-resistant depression (TRD).

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Anhedonia* / drug effects
  • Anhedonia* / physiology
  • Antidepressive Agents* / therapeutic use
  • Cross-Sectional Studies
  • Depressive Disorder, Major* / drug therapy
  • Depressive Disorder, Treatment-Resistant / drug therapy
  • Europe
  • Female
  • Humans
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antidepressive Agents